盐酸埃克替尼治疗晚期非小细胞肺癌的疗效分析

Analysis of Curative Effect of Icotinib in Treatment of Non-small-cell Lung Cancer

目的探讨晚期非小细胞肺癌患者实施盐酸埃克替尼治疗的疗效。方法取2015年1月—2016年1月间该院收治的70例晚期非小细胞肺癌进行研究,根据患者治疗方法将患者分为支持组(n=35)和药物组(n=35),对所有支持组患者进行晚期恶性肿瘤支持治疗,对所有药物组患者实施晚期恶性肿瘤支持治疗+盐酸埃克替尼治疗,统计分析两组患者的疗效及安全性。结果药物组与支持组患者治疗3个月后KPS评分[(75.3±2.8)分vs(43.8±6.4)分]、治疗有效率(31.4%vs 11.4%)、病情控制率(89.2%vs 48.6%)、无进展生存期[(8.3±1.9)月vs(4.5±1.3)月]、总生存期[(10.4±0.5)月vs(7.1±0.4)月]相比明显较高(P<0.05);药物组与支持组患者发热、皮疹、消化道症状、转氨酶升高发生率(5.7%vs 2.9%)、(2.9%vs 0.0%)、(8.6%vs 2.9%)、(2.9%vs 0.0%)相比差异无统计学意义(P>0.05)。结论晚期非小细胞肺癌患者实施盐酸埃克替尼治疗效果优良,可延长患者生存期。

Objective To study the curative effect of icotinib in treatment of non-small-cell lung cancer.Methods 70 cases of patients with non-small-cell lung cancer admitted and treated in our hospital from January 2015 to January 2016 were selected and divided into two groups with 35 cases in each,the support group adopted the advanced malignant tumor support therapy,while the drug group adopted the support therapy and icotinib,and the curative effect and safety of the two groups were counted and analyzed.Results The KPS score in the drug group and in the support group after 3-month treatment was(75.3±2.8)vs(43.8±6.4),the treatment effective rate,disease control rate,median progression-free survival,total survival obviously increased,[31.4%vs 11.4%,89.2%vs 48.6%,(8.3±1.9)months vs(4.5±1.3)months(10.4±0.5)months vs(7.1±0.4)months](P<0.05),and there were no obvious differences in the incidence rates of fever,rash,digestive tract system,increased transaminase between the drug group and the support group(5.7%vs 2.9%,2.9%vs 0.0%,8.6%vs 2.9%,2.9%vs 0.0%)(P>0.05).Conclusion The effect of icotinib in treatment of non-small-cell lung cancer is good,which prolongs the survival of patients.